Tybost (cobicistat): an alternative to ritonavir for boosting antiretrovirals

Gilead has launched a new pharmacokinetic enhancer to increase plasma levels of protease inhibitors in adults with HIV.

Cobicistat is used for its ability to inhibit the activity of the cytochrome P450 enzyme (pictured) in the liver | SCIENCE PHOTO LIBRARY
Cobicistat is used for its ability to inhibit the activity of the cytochrome P450 enzyme (pictured) in the liver | SCIENCE PHOTO LIBRARY

Cobicistat has no inherent antiretroviral activity but is a strong CYP3A4 inhibitor that prevents the breakdown of HIV protease inhibitors which are metabolised via the CYP3A pathway, thereby increasing plasma levels of these drugs. It can be used instead of ritonavir in patients taking atazanavir or darunavir for the treatment of HIV-1 infection.

Tybost is available as a film-coated tablet containing 150mg cobicistat, to be taken once daily with food at the same time as atazanavir 300mg or darunavir 800mg. 

Interaction warning

Prescribers must be aware of the high potential of cobicistat for interaction with other drugs. Cobicistat strongly inhibits CYP3A4 and its use in combination with drugs that are extensively metabolised by this pathway and undergo a high degree of first-pass metabolism is contraindicated. Such drugs include amiodarone, quinidine, statins, alfuzosin, pimozide, sildenafil, oral midazolam and ergot derivatives.

Concomitant use of cobicistat with strong CYP3A4 inducers, such as carbamazepine, phenytoin, phenobarbital, rifampicin and St John's wort, is also contraindicated.

Cobicistat is not recommended for use in combination with drugs that are moderate to weak inhibitors or inducers of CYP3A4 and should be used with caution in patients taking any drug that is metabolised via the CYP3A metabolic pathway.

Cobicistat also inhibits the transporters P-glycoprotein, BCRP, MATE1, OATP1B1 and OATP1B3, and can result in increased plasma concentrations of drugs that are substrates of these transport systems.

Component of quadruple combination tablet

Until the launch of Tybost, cobicistat was available in the UK only as a component of the four-drug combination tablet Stribild, which also includes the integrase inhibitor elvitegravir and the nucleoside reverse transcriptase inhibitors emtricitabine and tenofovir. The inclusion of cobicistat, to prevent the metabolism of elvitegravir, allows Stribild to be given once daily.

View Tybost drug record

Further information: Gilead Sciences

Follow MIMS on Twitter

Sign up for MIMS bulletins


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.